Comparison of Carvedilol and Atorvastatin for Preventing of Contrast-Induced Nephropathy.

Contrast-induced Nephropathy Clinical Trial

— CIN  

Official title:

Comparison of Carvedilol and Atorvastatin for Prevention of Contrast-Induced Nephropathy After Cardiac Catheterization

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03867994
• Other study ID #: beta-blockers and statins
• Status: Completed
• Phase: Phase 2
• Start date: February 1, 2016
• Est. completion date: May 15, 2017

Study information

• Verified date: March 2019
• Source: October 6 University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This prospective study is intended to evaluate if carvedilol has any potential protective effect over atorvastatin on the development of contrast-induced nephropathy (CIN) following cardiac catheterization in patients with moderate to high risk for CIN.

Description:

This study enrolled 150 patients planned for CC, and randomly assigned for one of the three groups. Group (A)include 49 patients who received two atorvastatin dose 80 mg 12 hours before CC and 40 mg just before CC. Group (B) include 48 patients who received 12.5 mg carvedilol twice daily for 7 days before CC and continue for 24hrs after the day of CC, Group (C) include 47 patients who only hydrated with saline. All included patients were hydrated with saline intravenous 0.9 sodium chloride (NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization. Serum creatinine(Scr), blood urea nitrogen (BUN) and estimated glomerular filtration rate were evaluated at the baseline and after 48 from CC. Serum neutrophil-associated lipocalin (NGAL) was evaluated after 4 hours from CC.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 144
• Est. completion date: May 15, 2017
• Est. primary completion date: May 15, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients aged between 18 and 70 years.

• Serum creatinine = 1.5 mg/dL.

• Using a moderate dose of atorvastatin (40 mg or equivalent dose of other statins).

• Moderate to high-risk for CIN.

Exclusion Criteria:

• Patients suffering from ST-segment elevation myocardial infarction (STEMI)

• Patients need for immediate cardiac catheterization

• Elevated liver enzymes (Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) three times the upper limit of normal).

• Active infection.

• Any contraindication to carvedilol, or atorvastatin.

• Patients on regular use of vitamins, minerals.

• Using medication with antioxidant properties e.g., beta-carotene, vitamin E, vitamin C, selenium, theophylline or N-acetyl cysteine 7 days prior to CC.

• Hemodynamically unstable patients (defined as abnormal or unstable blood pressure, especially hypotension (blood pressure less than 90/60 mm Hg).

• Patients who required dialysis.

• Pregnancy.

• Using of carvedilol in the past three months.

• Using a nephrotoxic agent in the past 48 hours or exposure to a contrast agent in the past 7 days prior to cardiac catheterization.

Related Conditions & MeSH terms

• Contrast-induced Nephropathy
• Kidney Diseases

Intervention

Drug:
• Atorvastatin

• Carvedilol

• saline

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
rabab ahmed mohamed	Cairo University

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Blood urea nitrogen (BUN)	BUN was assayed using modified Urease-Berthelot Method (Egyptian company of biotechnology, Cairo. Egypt)	On admission, and re-calculated 48 hours post CC using
Other	Serum Neutrophil gelatinase - associated lipocalin (NGAL) Description: . NGAL was assayed by enzyme -linked immunosorbent assay ELISA (Glory Science Co., Ltd, CHINA).	. NGAL was assayed by enzyme -linked immunosorbent assay ELISA (Glory Science Co., Ltd, CHINA).	Baseline was measured from venous blood before the initiation of hydration, and 4 hours after CC procedure.
Primary	development of contrast induced nephropathy	CIN :(defined as absolute rise in the baseline serum creatinine concentration by 0.5 mg/dL after 48 hours from CC).	1. Serum creatinine baseline was measured from venous blood (before initiating the hydration) and 48 hours after the CC procedure.
Secondary	Estimated Glomerular filtration rate (eGFR)	Cockcroft-Gault equation was used to calculate (eGFR)	on admission, and re-calculated 48 hours post CC using